Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for chinese MS patients: fingolimod shows promise in reducing relapses

NCT ID NCT04667949

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well and how safely the drug fingolimod (Gilenya) works for people in China with relapsing multiple sclerosis (RMS), a condition where the immune system attacks the nerves. Over 24 months, 98 participants took a daily 0.5 mg pill. The main goal was to see if it lowered the number of MS attacks (relapses). The study also tracked side effects. Fingolimod is not a cure, but it helps control the disease by reducing flare-ups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS (RMS)

Contacts and locations

Locations

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100000, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510623, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510630, China

  • Novartis Investigative Site

    Zhengzhou, Henan, 450052, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430030, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215004, China

  • Novartis Investigative Site

    Changchun, Jilin, 130021, China

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    Wenzhou, Zhejiang, 325000, China

  • Novartis Investigative Site

    Beijing, 065001, China

  • Novartis Investigative Site

    Beijing, 100028, China

  • Novartis Investigative Site

    Guangzhou, 510260, China

  • Novartis Investigative Site

    Shanghai, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.